Candel Therapeutics (NASDAQ:CADL) Stock Price Down 7% – Should You Sell?

Candel Therapeutics, Inc. (NASDAQ:CADL)’s stock price was down 7% during trading on Thursday . The stock traded as low as $11.38 and last traded at $11.32. 1,010,048 shares were traded during trading, a decline of 32% from the average session volume of 1,490,628 shares. The stock had previously closed at $12.17.

Wall Street Analyst Weigh In

CADL has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a report on Friday, July 17th. UBS Group reissued a “buy” rating on shares of Candel Therapeutics in a research report on Monday, August 17th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Candel Therapeutics in a research report on Thursday, August 13th. Stifel Nicolaus assumed coverage on Candel Therapeutics in a research note on Monday, July 13th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Candel Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $19.29.

Candel Therapeutics Trading Down 7.2%

The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09. The business has a 50-day simple moving average of $11.11 and a two-hundred day simple moving average of $8.31. The stock has a market cap of $863.91 million, a price-to-earnings ratio of -8.03 and a beta of -0.48.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28). Equities analysts forecast that Candel Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Insider Transactions at Candel Therapeutics

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the transaction, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at $922,380. This represents a 8.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Francesca Barone sold 23,447 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the sale, the insider owned 77,362 shares of the company’s stock, valued at $778,261.72. This trade represents a 23.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 37,447 shares of company stock valued at $390,017. 14.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Candel Therapeutics

Large investors have recently made changes to their positions in the company. WINTON GROUP Ltd bought a new stake in Candel Therapeutics in the 2nd quarter valued at $384,000. Squarepoint Ops LLC bought a new position in Candel Therapeutics during the 2nd quarter worth $775,000. California State Teachers Retirement System lifted its holdings in shares of Candel Therapeutics by 177.0% during the second quarter. California State Teachers Retirement System now owns 6,571 shares of the company’s stock worth $638,000 after buying an additional 4,199 shares in the last quarter. AXQ Capital LP boosted its position in shares of Candel Therapeutics by 50.8% in the second quarter. AXQ Capital LP now owns 31,460 shares of the company’s stock valued at $324,000 after acquiring an additional 10,596 shares during the period. Finally, Cookson Peirce & Co. Inc. bought a new stake in shares of Candel Therapeutics in the second quarter valued at about $618,000. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.